Topic
Every Four Weeks
About: Every Four Weeks is a research topic. Over the lifetime, 57 publications have been published within this topic receiving 833 citations.
Papers published on a yearly basis
Papers
TL;DR: A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous gemcitabine (GEM) as adjuvant chemotherapy for patients with curatively resected pancreatic cancer.
Abstract: A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous gemcitabine (GEM) as adjuvant chemotherapy for patients with curatively resected pancreatic cancer. Patients are enrolled within 10 weeks after pancreatectomy to be treated for six months after assignment to either S-1 (80 mg/m(2)/day for four weeks, repeated similarly every six weeks for a total of four courses) or GEM (1000 mg/m(2) on days 1, 8 and 15, repeated similarly every four weeks for a total of six courses). The primary endpoint is overall survival; secondary endpoints include relapse-free survival, incidence of adverse events and health-related quality of life. Each treatment arm includes 180 patients, providing an expected hazard ratio of 0.87 and an upper margin of 1.25 (two-sided alpha-error, 0.05; power, 0.8). Follow-up abdominal computed tomography is repeated every three months during the first two years, then every six months for three years.
99 citations
TL;DR: Alb‐IFN administered q2wk or q4wk may offer comparable efficacy, with an improved dosing schedule, compared with PEG‐ifNα‐2a, in patients with genotype 1, chronic hepatitis C.
82 citations
Journal Article•
TL;DR: The two combinations achieved response rapidly, required careful supervision, and were especially useful in treating patients with usually poor prognostic features.
61 citations
TL;DR: Two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks are recaptured following this multicenter cohort study on Crohn's disease.
59 citations
TL;DR: The preliminary antitumor activity documented in a patient with advanced pancreatic cancer and the striking preclinical antitumour effects of irofulven observed on intermittent dosing schedules support further disease-directed evaluations of this agent on the schedule evaluated in this study.
Abstract: PURPOSE: To evaluate the toxicity and pharmacologic behavior of the novel mushroom-derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion daily for 5 days every 4 weeks to patients with advanced solid malignancies. PATIENTS AND METHODS: In this phase I trial, 46 patients were treated with irofulven doses ranging from 1.0 to 17.69 mg/m2 as a 5-minute IV infusion (two patients received a 1-hour infusion) daily for 5 days every 4 weeks. The modified continual reassessment method was used for dose escalation. Pharmacokinetic studies were performed on days 1 and 5 to characterize the plasma disposition of irofulven. RESULTS: Forty-six patients were treated with 92 courses of irofulven. The dose-limiting toxicities on this schedule were myelosuppression and renal dysfunction. At the 14.15-mg/m2 dose level, renal dysfunction resembling renal tubular acidosis occurred in four of 10 patients and was ameliorated by prophylactic IV hydration. The 17.69-mg/m2 dose level was not tolerated bec...
54 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |